(Q44592866)

4 December 2017

Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide (English)

1 reference

4 December 2017

Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide (English)

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

13 March 2024

1 reference

G. Van Camp

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504342

13 March 2024

A. Flamez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504342

13 March 2024

B. Cosyns

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504342

13 March 2024

J. Goldstein

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504342

13 March 2024

C. Perdaens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504342

13 March 2024

D. Schoors

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504342

13 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

23 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14504342

full work available at URL

13 March 2024

https://www.neurology.org/doi/pdfdirect/10.1212/01.WNL.0000083985.00343.F2

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

13 March 2024

1 reference

4 December 2017

61

1 reference

4 December 2017

6

1 reference

4 December 2017

859-861

1 reference

High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa

13 March 2024

2

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

The effect of pregnancy in Parkinson's disease.

13 March 2024

3

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Cardiac murmurs and endocardial fibrosis associated with methysergide therapy

13 March 2024

4

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Development of heart valve lesions during methysergide therapy

13 March 2024

5

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Valvular heart disease associated with fenfluramine-phentermine

13 March 2024

6

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Appetite suppressants and valvular heart disease

13 March 2024

7

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Fibrotic valvular heart disease subsequent to bromocriptine treatment

13 March 2024

8

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Pergolide in the treatment of patients with early and advanced Parkinson's disease

13 March 2024

9

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

Valvular heart disease in patients taking pergolide

13 March 2024

10

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000083985.00343.F2

13 March 2024

Identifiers

1 reference

4 December 2017

1 reference